Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMTM monotherapy in Chinese participants with Alzheimer's disease
CTR20250032Phase 3Terminated
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydromethylthionine mesylate in Alzheimer's disease (AD), sponsored by TauRx Therapeutics Ltd. Started Jan 2025; status: terminated.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20250032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250032.